Imperagen Awarded Share of £13.5 Million UKRI Engineering Biology R&D Fund

Imperagen is proud to be among 48 leading UK companies selected to receive a share of the £13.5 million in funding from UK Research and Innovation (UKRI) to support innovation in engineering biology.

The £350,000 award will accelerate our work on the Digital Enzyme Evolution™ platform, helping us further enhance AI-driven enzyme design, physics-based modelling, and automated lab workflows—enabling faster, more scalable biocatalyst development across pharmaceuticals, life sciences, and industrial biotechnology.

“This funding is a strong validation of the work we’ve been doing to transform enzyme engineering into a truly digital process,” said Dr. Andrew Currin, Chief Scientific Officer at Imperagen. “It allows us to push forward with ambitious R&D goals that will make enzyme innovation faster, smarter, and more accessible – delivering real-world impact across multiple industries.”

We’re honored to be recognized alongside a cohort of forward-thinking UK companies committed to advancing the field of synthetic and engineering biology.

Read more about the programme and recipients here:

https://www.ukri.org/news/13-5-million-for-48-engineering-biology-rd-projects/